Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
VBCC Perspectives
We Must Incorporate Value into Our Decision-Making Process
By
John L. Marshall, MD
Economics & Value
,
Value-Based Care
,
VBCC Perspectives
November 2012, Vol 3, No 8
We should all read with great interest the New York Times opinion piece by Peter B. Bach, MD, and colleagues from Memorial Sloan-Kettering Cancer Center on their rationale for not including ziv-aflibercept (Zaltrap) in its formulary for patients with metastatic or advanced colorectal cancer.
Read Article
Can Value-Based Cancer Care Address the Challenges Faced by Specialty Pharmacies in Oncology?
By
Atheer A. Kaddis, PharmD
Economics & Value
,
Value-Based Care
,
VBCC Perspectives
March 2012, Vol 3, No 2
Specialty pharmacies are facing specific challenges in the ways they interact with payers, providers, and even with the pharmaceutical industry in relation to access and delivery of cancer drugs.
Read Article
The Promise of Molecular Profiling
By
Caroline Helwick
Economics & Value
,
Value-Based Care
,
VBCC Perspectives
February 2012, Vol 3, No 1
At the 2012 Gastrointestinal Cancers Symposium, Value-Based Cancer Care (VBCC) asked Al B. Benson, III, MD, FACP, Professor of Medicine, Associate Director for Clinical Investigations, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Immediate Past President, ACCC, and editorial board member of VBCC, to discuss the growing importance of molecular profiling in cancer care.
Read Article
Clinical and Economic Impact of Multiple Myeloma
By
Matthew Mitchell, PharmD, MBA
Economics & Value
,
Value-Based Care
,
VBCC Perspectives
December 2011, Vol 2, No 7
The clinical and economic impact of multiple myeloma is tremendous. With the onset of novel therapies used in multiple myeloma, as well as the release of new data demonstrating progression-free survival and overall survival, therapy used in multiple myeloma is now on the radar for payers, despite the relatively low incidence of the disease.
Read Article
The New Era of Personalized Medicine in Oncology: Novel Biomarkers Ushering in New Approaches to Cancer Therapy
By
Steve Stricker, PharmD, MS, BCOP
Value-Based Care
,
VBCC Perspectives
October 2011, Vol 2, No 6
It is next to impossible for a day to go by without thinking about the contributions of personalized medicine to the care of patients living with cancer. Whether we are treating a newly diagnosed patient with HER2/neupositive breast cancer using trastuzumab, or using erlotinib in the management of a patient with non–small-cell lung cancer (NSCLC) whose tumor harbors specific mutations in the epidermal growth factor receptor genes, individualizing therapy based on molecular biology and genetic testing has become commonplace in contemporary oncology practice.
Read Article
The Challenge of Value-Based Care in Oncology: Improving Clinical Outcomes
Economics & Value
,
Value-Based Care
,
VBCC Perspectives
June 2011, Vol 2, No 3
The focus on value in patient care has taken a prominent place in any discussion related to improving care delivery, but no agreement exists on what that “value” is.
Read Article
The Potential for Personalized Medicine to Improve the Value of Targeted Therapy
By
Yu-Ning Wong, MD, MSCE
Economics & Value
,
Value-Based Care
,
VBCC Perspectives
April 2011, Vol 2, No 2
Read Article
The Costs of Care: A Discussion We’re Not Prepared to Have—Yet
By
Denise K. Pierce
Value-Based Care
,
VBCC Perspectives
November/December 2010, Vol 1, No 6
Each year, oncologists return to their respective practices after attending the annual American Society of Clinical Oncology or American Society of Hematology meetings armed with knowledge of new drug/biologic combinations, modified regimen dosing, and other novel approaches that may provide incrementally better outcomes for cancer patients.
Read Article
Resource Allocation for Colorectal Cancer Screening
By
Naimish Pandya, MD
VBCC Perspectives
October 2010, Vol 1, No 5
Read Article
New Prostate Cancer Therapies Raise New Issues
By
Lee N. Newcomer, MD, MHA
Value-Based Care
,
VBCC Perspectives
September 2010, Vol 1, No 4
Prostate cancer patients have 2 new therapeutic options this summer with the approvals of sipuleucel-T and cabazitaxel. The former drug is an important scientific advance as one of the pioneering cancer vaccines to show a prolongation of survival.
Read Article
Page 4 of 5
1
2
3
4
5
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma